Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMUX
HOLDREMOVEImmunic, Inc. · Healthcare · United States · $199M · Avg Vol: $4M/d
An early-stage biotechnology company with no commercialized products, negative cash flows, and high binary clinical trial risk. It fails our quality and margin of safety requirements.
COMPANY DESCRIPTION
Immunic, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral small molecule therapies for chronic inflammatory and autoimmune diseases. The company's pipeline includes drug candidates targeting pathways involved in conditions such as multiple sclerosis, psoriasis, and inflammatory bowel disease. Its competitive strategy centers on identifying and advancing innovative compounds with the potential to address significant unmet medical needs in immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| EPS | -10.91 | -7.00 | -10.00 | -6.20 | — |
| Shares | 13.6M | 13.6M | 9.0M | 12.0M | -11.6% |
| Debt | 1.6M | 1.3M | 1.0M | 0.6M | -28.3% |
| Equity | 113.7M | 28.9M | 18.4M | -6.7M | -59.7% |
| Op CF | -65.1M | -70.8M | -84.8M | -85.8M | — |
| Inv CF | -9.7M | 9.5M | -0.3M | -0.2M | — |
| Fin CF | 95.8M | 1.0M | 74.5M | 65.6M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMUX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMUX | Immunic, Inc.(you) | $199M | 48 | HOLD |
| NKTX | Nkarta, Inc. | $205M | 42 | HOLD |
| DTIL | Precision BioSciences, Inc. | $179M | 43 | HOLD |
| EQ | Equillium, Inc. | $185M | 41 | HOLD |
| UNCY | Unicycive Therapeutics, Inc. | $210M | 39 | HOLD |
| FENC | Fennec Pharmaceuticals Inc. | $319M | 46 | HOLD |
| NAGE | Niagen Bioscience, Inc. | $278M | 54 | HOLD |
| KPTI | Karyopharm Therapeutics Inc. | $202M | 34 | SELL |
| ELDN | Eledon Pharmaceuticals, Inc. | $313M | 42 | HOLD |
| VTVT | vTv Therapeutics Inc. | $132M | 41 | HOLD |
Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%